Basilea Pharmaceutica AG announced that strong sales of its antifungal medication Cresemba® (isavuconazole) in the Asia Pacific region and China, through its license partner Pfizer Inc., have surpassed a sales threshold, triggering a USD 5 million milestone payment to Basilea. The company reported that Cresemba is now marketed in more than 75 countries, with total global in-market sales reaching USD 693 million in the twelve-month period from October 2024 to September 2025, representing a 27 percent year-on-year growth. Cresemba is identified as the largest branded antifungal for invasive fungal infections worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 1001163604) on February 09, 2026, and is solely responsible for the information contained therein.